Late-Stage Pipeline Blooming At Boehringer As R&D Spend Soars

Jardiance And Ofev Sales Continue To Climb

Over the next five years, the German group is looking to invest over €25bn in the R&D pipeline, with oncology a key focus.

BI management
• Source: Boehringer Ingelheim

Boehringer Ingelheim GmbH has set an ambitious goal of up to 15 new product launches through 2025 backed by a €4.1bn R&D spend in 2021, nearly 12% up on the previous year and the highest investment in the 137-year history of the German family-owned company.

Speaking at the firm's annual press conference on 5 April, chairman Hubertus von Baumbach noted that over the next five...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.